It is the first membrane-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT), developed at the University of Texas in 2017
The Complete Fat Cell Targeting Pathway When AOD-9604 reaches adipose tissue following administration, it initiates the following sequence: 1
Unlike GLP-1 agonists that reduce appetite or growth hormone peptides that stimulate lipolysis, the compound addresses fat metabolism at the enzymatic level: it removes the molecular governor that locks adipocytes into a low-energy-expenditure state, potentially restoring normal metabolic function in fat tissue where NNMT is overexpressed
If you have low B12 levels, is compounded semaglutide with B12 the answer
"Is there a "gold standard" for human serum vitamin B12 assay?"
Formulated for advanced studies examining metabolic regulation, mitochondrial activity, and peptide signaling pathways in model systems